Truxima 500 mg in 50 mL Injection
RxNorm 2105835
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2105835 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Truxima 500 mg in 50 mL Injection.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Semantic Branded Drug (SBD):
50 mL rituximab-abbs 10 mg/ML Injection [Truxima]
(Atom ID: 10782236)
Tall Man Lettering Synonym (TMSY):
50 mL riTUXimab-abbs 10 mg/ML Injection [Truxima]
(Atom ID: 10782268)
Synonym (SY):
50 mL Truxima 10 mg/ML Injection
(Atom ID: 10782238)
Prescribable Name (PSN):
Truxima 500 mg in 50 mL Injection
(Atom ID: 10782237)
Synonym (SY):
Truxima 500 mg per 50 mL Injection
(Atom ID: 10782239)
Patient Education
Rituximab Injection
Rituximab injection products are used alone or with other medications to treat various types of non-Hodgkin's lymphoma (NHL; a type of cancer that begins in a type of white blood cells that normally fights infection). Rituximab injection products are also used with other medications to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Rituximab injection (Rituxan) is also used with methotrexate (Otrexup, Rasuvo, Xatmep, others) to treat the symptoms of rheumatoid arthritis (RA; a condition in which the body attacks its own joints, causing pain, swelling, and loss of function) in adults who have already been treated with a certain type of medication called a tumor necrosis factor (TNF) inhibitor. Rituximab injection (Rituxan, Ruxience) is also used in adults and children 2 years of age and older along with other medications to treat granulomatosis with polyangiitis (Wegener's Granulomatosis) and microscopic polyangiitis, which are conditions in which the body attacks its own veins and other blood vessels, which causes damage to organs, such as the heart and lungs. Rituximab injection (Rituxan) is used to treat pemphigus vulgaris (a condition that causes painful blisters on the skin and the lining the mouth, nose, throat and genitals). Rituximab injection products are in a class of medications called monoclonal antibodies. They treat the various types of NHL and CLL by killing cancer cells. Certain rituximab injection products also treat rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris by blocking the activity of the part of the immune system that may damage the joints, veins, and other blood vessels.
[Learn More]
Cancer Chemotherapy
Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.
You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.
Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).
NIH: National Cancer Institute
[Learn More]
* Please review the disclaimer below.
